[Featured Stock] Nature Cell Hits Upper Limit on News of US FDA 'Breakthrough Therapy' Designation

Naturecell's stock price hit the upper limit following the news that it received the 'Breakthrough Therapy' designation from the U.S. Food and Drug Administration (FDA).

As of 9:05 a.m. on the 24th, Naturecell was trading at 220,200 KRW, soaring 29.75% (5,090 KRW) compared to the previous session, reaching the daily upper limit.

The surge in stock price was driven by the news of Naturecell's breakthrough therapy designation. On the 21st, Naturecell announced that JointStem, currently in clinical trials in the U.S., was recognized as a 'Breakthrough Therapy' by the FDA in the cell therapy field, marking the first Korean company to receive this designation.

When designated as a Breakthrough Therapy (BTD), the product not only qualifies for Fast Track designation but also receives intensive support from the FDA for efficient drug development. This increases the likelihood of product approval and shortens the drug development period.

JointStem is the world's first autologous adipose-derived mesenchymal stem cell therapy for patients with severe knee osteoarthritis. It is reported that a single local injection into the knee joint cavity promotes cartilage regeneration, resulting in pain reduction and improved joint function that can last for at least three years.